New integrated design, enhanced connectivity, and streamlined hardware mark a major evolution in Freespira’s digital therapeutics platform
KIRKLAND, Wash., Feb. 10, 2026 — Freespira, developer of the first FDA-cleared at-home treatment for anxiety disorders, including panic disorder and post-traumatic stress disorder (PTSD), today announced the launch of FST5, its fifth-generation device that, for the first time, combines the sensor and display into a user-friendly single unit.
Freespira is the only medication-free, prescription device used in a treatment targeting physiological root causes of anxiety disorder symptoms using real-time software-driven respiratory guidance and one-on-one video coaching to correct the respiratory dysfunction commonly underlying these disorders.
“The launch of the FST5 reflects our commitment to continually improving both clinical outcomes and the user experience,” said Joe Perekupka, CEO of Freespira. “By integrating the sensor and display into one device and expanding connectivity options, we are making it easier than ever for patients to engage with our proven therapy while maintaining the clinical precision providers expect.”
Launched in late 2025, the FST5 has combined previously separate components into a fully integrated sensor and display. Setup complexity is reduced, accessories are minimized, and the overall patient experience is improved while maintaining Freespira’s reputation for reliability and accuracy.
A hospital-grade NDIR (non-dispersive infrared) CO₂ measurement module provides accurate, real-time monitoring of respiration and end-tidal CO₂, and the new model no longer requires weekly calibration.
The new platform supports Wi-Fi connectivity and cellular data as standard, with seamless switching for in-home or clinical environments with limited Wi-Fi.
Other improvements include a single charger with an integrated cable, making for more convenient daily use for patients and providers.
The FST5 is the culmination of more than a decade of experience, following the FS1 and FS2 systems introduced in 2014 and the FS3 platform in 2018. In 2026, the FST5 sets a new standard for capnography-guided respiratory intervention (CGRI).
###
About Freespira, Inc.
Freespira, Inc. is the maker of Freespira, the only FDA-cleared digital therapeutic treatment proven to significantly reduce or eliminate panic attacks, panic disorder, and post-traumatic stress disorder (PTSD) symptoms in just 28 days. Health plans, self-insured employers, and the Veterans Administration provide the company’s medication-free solutions to improve quality of life, reduce medical expenditures, and support the appropriate use of valuable healthcare resources. Find out how at freespira.com.